Search Results

Now showing 1 - 1 of 1

Add to my favorites
Highlight selection of radiochemistry and radiopharmacy developments by editorial board
(2023) Passchier, J. (Jan); Rey, A. (Ana); Laverman, P. (Peter); Cheng, Z. (Zhen); Peñuelas-Sanchez, I. (Ivan); Chauvet, A.F. (Alan Faivre); Guillet, B. (Benjamin); Perk, L. (Lars); Zhang, M.R. (Ming Rong); Jalilian, A. (Amir); Patt, M. (Marianne); Cleeren, F. (Frederik); Vercouillie, J. (Johnny); Zhu, H. (Hua); Kiss, O.C. (Oliver C.); Scott, P.J.H. (Peter J. H.); Dam, M. (Michael) van; Alves, F. (Francisco); Aime, S. (Silvia); Engle, J. (Jonathan)
Background: The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development. Main body: This selection of highlights provides commentary on 21 different topics selected by each coauthoring Editorial Board member addressing a variety of aspects ranging from novel radiochemistry to first-in-human application of novel radiopharmaceuticals. Conclusion: Trends in radiochemistry and radiopharmacy are highlighted. Hot topics cover the entire scope of EJNMMI Radiopharmacy and Chemistry, demonstrating the progress in the research field, and include new PET-labelling methods for 11C and 18F, the importance of choosing the proper chelator for a given radioactive metal ion, implications of total body PET on use of radiopharmaceuticals, legislation issues and radionuclide therapy including the emerging role of 161Tb.